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Background. Short-term (48-week) results of the OPTIONS trial showed that nucleoside reverse transcriptase inhibitors (NRTIs) 
can be safely omitted from salvage therapy as long as the regimen has a cumulative activity of >2 active antiretroviral medications. The 
long-term durability of this approach and outcomes in persons who have more-extensive HIV-1 drug resistance are uncertain.
Methods. Participants with virologic failure and anticipated antiretroviral susceptibility received an optimized regimen and 
were randomized to omit or add NRTIs. A separate group with more resistance (cumulative activity ≤2 active agents) received an 
optimized regimen including NRTIs.
Results. At week 96, among 360 participants randomized to omit or add NRTIs, 70% and 65% had HIV-1 RNA <200 copies/
mL, respectively. Virologic failure was uncommon after week 48. Younger age and starting fewer new antiretroviral medications 
were associated with higher odds of virologic failure. In the highly resistant group, 53% had HIV-1 RNA <200 copies/mL at week 96.
Conclusions. HIV-1 salvage therapy can safely omit NRTIs without compromising efficacy or durability of response as long as 
the new regimen has a cumulative activity of >2 active drugs. Younger people and those receiving fewer new antiretrovirals require 
careful monitoring. Even among individuals with more-extensive resistance, most achieve virologic suppression.
Clinical Trials Registration. NCT00537394.
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In people with human immunodeficiency virus-1 (HIV-1) in-
fection (PWH) who have virologic failure on antiretroviral 
therapy (ART), guidelines recommend starting at least 2, and 
preferably 3, new active antiretroviral medications [1]. The 
question of whether nucleoside reverse transcriptase inhibitors 
(NRTIs) should be included in a new regimen when other ac-
tive agents are available was addressed in the OPTIONS trial 
(AIDS Clinical Trials Group [ACTG] A5241) [2]. In this study, 
participants who were failing protease inhibitor (PI)-based 
therapy but whose virus was sensitive to a new regimen with a 
cumulative activity of >2 active agents were randomized to add 
or omit NRTIs from their new regimen. At week 48, the omit 
NRTIs group was not inferior to the add NRTIs group for the 
primary outcome of regimen failure [2].
The initial report of the OPTIONS trial findings focused on 
week 48 results (primary outcome) leaving important questions 
unanswered, such as the long-term durability of the 2 strategies. 
In addition, the impact of NRTIs on metabolic outcomes and 
quality of life (QOL) were not described. Now, we report on the 
virologic responses through 96 weeks (end of study follow-up) 
and factors associated with virologic failure. In participants 
who experienced virologic failure, we describe the frequency 
and type of treatment-emergent drug resistance. Because of the 
importance of safety and tolerability with long-term ART, we 
present the metabolic, renal, and self-reported QOL outcomes.
In addition to the 2 groups that were randomized to omit or 
add NRTIs, OPTIONS included a third, nonrandomized group 
with more drug resistance (sensitive only to a regimen with a 
cumulative phenotypic susceptibility score of ≤2 active agents 
as opposed to >2 in the randomized groups). Based on treat-
ment history and resistance testing, the participants in this 
group were treated with a combination of active and partially 
active agents that included NRTIs. Here, for the first time, we 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
report the outcomes following treatment in these individuals 
with highly drug-resistant HIV-1.
METHODS
The OPTIONS design, eligibility criteria, and procedures were 
previously described [2]. OPTIONS (NCT00537394) was an 
open-label, phase III, partially randomized strategy trial in 
treatment-experienced PWH (failing PI-based regimen with 
triple-class experience or drug resistance [nonnucleoside re-
verse transcriptase inhibitors, NNRTIs, NRTIs, and PIs]) that 
used a continuous phenotype susceptibility score (cPSS) to se-
lect an optimized antiretroviral regimen. The cPSS is the sum 
of the predicted activity of antiretrovirals (excluding NRTIs) in 
each study regimen [3]. An optimized regimen was the combi-
nation of antiretrovirals with the highest cPSS that was accept-
able to the participant and local study investigators. Optimized 
regimens and NRTIs were recommended based upon treat-
ment history, viral resistance, and coreceptor tropism test 
results (PhenoSense GT and Trofile, respectively; Monogram 
Biosciences). Participants who had previously received 
enfuvirtide or an integrase strand transfer inhibitor (INSTI) 
were presumed to be resistant to these agents. Participants with 
cPSS >2 were randomly assigned to receive their optimized reg-
imen only (omit NRTIs group) or to add NRTIs (add NRTIs 
group) to their optimized regimen, stratified by INSTI expe-
rience and choice of maraviroc-containing study regimen. 
A separate group of participants with cPSS ≤2 (highly resistant 
group) were directly assigned to receive an optimized regimen 
and add NRTIs. Optimized regimens, consisting of medications 
available at the time of the trial, were composed of 3 or 4 of the 
following: ritonavir-boosted darunavir or tipranavir, raltegravir, 
etravirine, maraviroc, or enfuvirtide. All participants were in 
the United States and provided informed consent in compliance 
with US Department of Health and Human Services guidelines.
Procedures and Outcomes
Study evaluations occurred before entry, at entry, weeks 1, 4, 8, 
12, 16, and 24, and every 12 weeks thereafter through week 96. 
The primary efficacy outcome was regimen failure, which was 
a composite outcome of first confirmed virologic failure or dis-
continuation of NRTI assignment. Virologic failure was defined 
as any 1 of the following (with confirmation on repeat measure-
ment): <1 log10 copies/mL HIV-1 RNA decrease from baseline 
to week 12; virologic rebound to >200 copies/mL after suppres-
sion to <200 copies/mL; lack of suppression to <200 copies/
mL by week 24; or HIV-1 RNA ≥200 copies/mL at or after 
week 48. Following intention-to-treat principles, participants 
who experienced virologic failure or who discontinued their 
assigned NRTI strategy (primary study endpoint) continued 
to be followed through 96 weeks to be evaluated for secondary 
outcomes. Secondary outcomes included: change in CD4 cell 
count from baseline; occurrence of newly acquired HIV-1 drug 
resistance or tropism shift between baseline and confirmed 
virologic failure; change in lipids from baseline; change in car-
diovascular risk score from baseline; and change in QOL scores 
from baseline. Fasting lipids were collected at entry, and weeks 
24, 48, and 96. QOL was assessed at baseline, weeks 8 and 24, 
and every 24 weeks thereafter using the general health score, 
which uses a visual analog scale that ranges from 0 (worst pos-
sible health) to 100 (perfect health). Cardiovascular risk was 
assessed using the Framingham risk score as this study was 
completed in 2011 prior to the introduction of newer guidelines 
for assessing risk.
Statistical Analysis
Calculating percentages of participants with HIV-1 RNA 
below limits used 2 methods: observed analysis included only 
participants with an observed RNA result; imputed analysis 
included all participants and missing values were imputed as 
greater than limit.
Cumulative probability of regimen or virologic failure by 96 
weeks was estimated using a stratified Kaplan–Meier estimator. 
Stratum-specific estimates by group used inverse variance 
weights. Confidence intervals (CIs) used log(–log)-transformed 
Greenwood-estimated variance. Participants without regimen 
failure were censored at last visit. Noninferiority was concluded 
if the upper 95% confidence bound of the treatment difference 
was <15%.
Secondary outcomes used marginal modeling with 
generalized estimating equations incorporating equicorrelation 
structure for continuous outcomes and independence correla-
tion and logit link for dichotomous outcomes. Nonlinear time 
trends were included as suggested by goodness of fit using 
Quasi-AIC.
Association of baseline characteristics with observed 
virologic failure in the randomized groups used logistic regres-
sion, a stepwise covariate selection process, reparameterization 
of covariates exhibiting nonlinearity in the logit, and testing for 
all 2-way statistical interactions in the main-effects model.
RESULTS
Study Participants
A total of 413 participants enrolled. Three hundred-sixty 
participants with cPSS of >2 were randomized to receive 
an optimized regimen without NRTIs (omit NRTIs group, 
n  =  179) or an optimized regimen that added NRTIs (add 
NRTIs group, n = 181). An additional 53 participants who had 
highly resistant virus received an optimized regimen with a 
cumulative activity of 2 or fewer active agents (cPSS ≤ 2) and 
added NRTIs (highly resistant group). Table 1 summarizes 
baseline characteristics. Figure 1 shows participant dispo-
sition: 159 in the omit NRTIs group (89%), 158 in the add 
NRTIs group (87%), and 44 in the highly resistant group 
(83%) completed the study with a week 96 visit.











Group, n = 53 P Valuea
Age, y, median (Q1, Q3) 46 (40, 51) 46 (41, 52) 46 (40, 52) 43 (40, 50) .233d
Female sex, No. (%) 47 (26) 46 (25) 93 (26) 6 (11) .021e
Race/ethnicity, No. (%)
White non-Hispanic 55 (31) 59 (33) 114 (32) 18 (35) .885e
Black non-Hispanic 69 (39) 79 (44) 148 (41) 19 (37)
 Hispanic 46 (26) 37 (21) 83 (23) 14 (27)
 Other 8 (4) 4 (2) 12 (3) 1 (2)
Baseline CD4+, cells/mm3, median (Q1, Q3) 212 (105, 348) 193 (104, 376) 207 (104, 363) 85 (25, 232) <.001d
Baseline HIV-1 RNA, (log10 copies/mL, median (Q1, Q3) 4.2 (3.6, 4.6) 4.2 (3.6, 4.7) 4.2 (3.6, 4.6) 4.4 (4.1, 4.8) .023
d
Years of previous ARV exposure, median (Q1, Q3) 12 (9, 16) 10.7 (7.5, 14.0) 11.4 (0.5, 25.0) 13.1 (10.7, 16.5) .016d
Previous enfuvirtide or integrase inhibitor exposure, No. (%) 32 (18) 34 (19) 66 (18) 40 (75) <.001e
Screening HIV-1 tropism, No. (%)
 CCR5 88 (49) 89 (49) 177 (49) 10 (19) <.001e
 Dual/mixed 72 (40) 71 (39) 143 (40) 31 (58)
 CXCR4 8 (4) 10 (6) 18 (5) 8 (15)
 Nonreportable 11 (6) 11 (6) 22 (6) 4 (8)
Number of active NRTIs chosen prior to randomization, No. (%)b
 0 18 (10) 21 (12) 39 (11) 6 (11) .476e
 1 100 (56) 103 (57) 203 (56) 34 (64)
2 or 3 61 (34) 57 (31) 118 (33) 13 (25)
Total number of new ARVs, including NRTIs, started following 
randomization, No. (%)
 0 0 (0) 0 (0) 0 (0) 9 (17) <.001e
 1–2 17 (9) 9 (5) 26 (7) 15 (28)
 3 138 (77) 92 (51) 230 (64) 17 (32)
 4–6 24 (13) 80 (44) 104 (29) 12 (23)
Total cholesterol from all samples, mg/dL 
Median (Q1, Q3) 164 (140, 187) 164 (137, 192) 164 (139, 191) 178 (133, 207) .128d
Number missing 16 19 35 5
Non-HDL cholesterol from fasting samples, mg/dL
Median (Q1, Q3) 124 (101, 149) 131 (102, 156) 126 (101, 152) 140 (109, 171) .053d
Number missing 27 28 55 8
LDL cholesterol from all samples, mg/dL
Median (Q1, Q3) 90 (69, 115) 97 (69, 120) 93 (69, 117) 88 (62, 126) .963d
Number missing 30 30 60 10
Framingham risk score, %
Median (Q1, Q3) 7.4 (3.4, 13.2) 8.5 (3.7, 13.3) 8.1 (3.6, 13.3) 8.6 (5.5, 14.5) .200d
Number missing 12 18 30 4
Calculated creatinine clearance, mL/min
Median (Q1, Q3) 108.4 (86.5, 134.4) 107.0 (88.4, 127.3) 107.3 (87.1, 130.7) 105.3 (97.1, 
132.2)
.419d
Number missing 1 0 1 0
QOL score, point categories, No. (%)c
 0–60, quartile 1  47 (26) 51 (28) 98 (27) 10 (19) .123e
 61–75, quartile 2  42 (23)  38 (21) 80 (22) 9 (17)
 76–100, quartiles 3 and 4  83 (46)  89 (49) 172 (48) 34 (64)
 Missing 7 (4) 3 (2) 10 (3) 0 (0)
Baseline characteristics include the entire study sample except in cases where missing values are noted.
Abbreviations: ARV, antiretroviral; CCR5, C-C chemokine receptor 5-tropic virus; CXCR4, chemokine receptor type 4; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NRTI, nu-
cleoside reverse transcriptase inhibitor; QOL, quality of life.
aStatistical comparisons of baseline characteristics between combined randomized groups and highly resistant group.
bAn active NRTIs is defined to be either partially sensitive or sensitive from a net assessment by Monogram PhenoSense GT testing at screening.
cQuality of life categories defined by grouped quartiles as informed by correlates of virologic failure analysis.
dTwo sample Wilcoxon test with continuity correction.
eΧ2 test.
There were fewer deaths following treatment initiation in the 
omit NRTIs group than in the add NRTIs group (Figure 1): 1 
and 10, respectively; cumulative probability of death through 96 
weeks was 0.6% (95% CI, 0.1%–4%) and 5.7% (95% CI, 3.1%–
10.3%), respectively. Because of the small number of events, the 
95% CIs on the cumulative probabilities of death overlap. The 
cumulative probability of death through 96 weeks (2 deaths) in 
the highly resistant group (also receiving NRTIs) was 4% (95% 
CI, 1%–15.1%). The causes and timing of death were heteroge-
neous and there was no pattern suggesting a common mech-
anism or specific etiology.
Regimen and Virologic Failure
At week 96, 70% of all 179 participants in the omit NRTIs group 
and 65% of all 181 participants in the add NRTIs group had 
HIV-1 RNA <200 copies/mL; while 61% and 59% had HIV-1 
RNA <50 copies/mL, respectively (Supplementary Table 1). 
Among the 158 participants in each randomized group who 
had a week 96 HIV-1 RNA value (observed analysis), 79% in the 
omit NRTIs group and 75% in the add NRTIs group had HIV-1 
RNA <200 copies/mL; while 69% and 68% had HIV-1 RNA <50 
copies/mL, respectively.
The cumulative probability for regimen failure (virologic 
failure or discontinuation of NRTI assignment) at week 96 was 
33.6% in the omit NRTIs group and 31.3% in the add NRTIs 
group. The upper bound of the 95% CI on the difference in reg-
imen failure between randomized groups (omit–add) was 11.5% 
and, thus, noninferiority of omit versus add NRTIs (compared 
to the prespecified bound of 15%) was achieved. Most reg-
imen failures were due to virologic failure (46 of 60 in the omit 
NRTIs group, 50 of 57 in the add NRTIs group). By week 96, 
the estimated cumulative probability for virologic failure was 
28.2% in the omit NRTIs group and 30.2% in the add NRTIs 
group (Figure 2); the upper bound of the 95% CI on the differ-
ence between groups was 7.4% and, thus, the omit NRTIs group 
can be concluded to be noninferior to the add NRTIs group at 
a lower noninferiority threshold of 10%. Most virologic failures 
occurred in the first 48 weeks: only 15 of 104 (14%) virologic 
failures occurred in the randomized groups after week 48.
In the highly resistant group, at week 96, 53% (of 53 
participants) had HIV-1 RNA <200 copies/mL and 47% had 
HIV-1 RNA <50 copies/mL. Among 43 participants who had a 
week 96 HIV-1 RNA value (observed analysis), 65% had HIV-1 
RNA <200 copies/mL and 58% had HIV-1 RNA <50 copies/mL.
Change in CD4 Cell Count
At week 96, the mean CD4 cell count was 391/mm3 (95% CI, 
357–425) for the omit NRTIs group and 428/mm3 (95% CI, 383–
473) for the add NRTIs group. Mean increases in CD4 cell count
from baseline to week 96 were 143/mm3 (95% CI, 115–170) and
174/mm3 (95% CI, 145–203), respectively. In the highly resistant
group, the mean CD4 cell count at week 96 was 307/mm3 and the 
mean increase from baseline to week 96 was 133/mm3.
Baseline Factors Associated With Virologic Failure in the 
Randomized Groups
The following factors were significantly and independently associ-
ated with virologic failure in the randomized groups: age, number 
of active NRTIs chosen prior to randomization (regardless of treat-
ment arm), total number of new antiretrovirals started following 
randomization, and QOL score (Supplementary Table 2). Younger 
participants (age 16–46  years) had significantly higher odds of 
Randomized  to Group 1:
Omit NRTIs  Group
(n = 179)
Premature study discontinuation (n= 20)
• Deaths after treatment dispensation (n = 1)
• Severe debilitation (n = 0)
• Withdrew consent (n = 4)
• Not willing to adhere to study (n = 3)
• Not able to get to clinic (n = 7)
• Lost to study follow-up (n= 5)
Completed 96 week study visit (n = 159)
• Missing Week 96 RNA result (n = 1)
Premature study discontinuation (n= 23)
• Deaths before treatment dispensation (n = 1)
• Deaths after treatment dispensation (n = 10)
• Severe debilitation (n = 1)
• Withdrew consent (n = 2)
• Not willing to adhere to study (n = 1)
• Not able to get to clinic (n = 5)
• Lost to study follow-up (n= 2)
• Site is closing (n = 1)
Premature study discontinuation (n= 9)
• Deaths after treatment dispensation (n = 2)
• Severe debilitation (n = 1)
• Withdrew consent (n = 2)
• Not willing to adhere to study (n = 1)
• Not able to get to clinic (n = 1)
• lost to study follow-up (n = 2)
Completed 96 week study visit (n = 158)
• Missing Week 96 RNA result (n = 0)
Completed 96 week study visit (n = 44)
• Missing Week 96 RNA result (n = 1)
Randomized to Group 2:
Add NRTIs Group
(n = 181)





Figure 1. Participant disposition. Abbreviation: NRTI, nucleoside reverse transcriptase inhibitor.
virologic failure compared to older participants (age 47–69 years) 
(adjusted odds ratio [AOR], 4.4; 95% CI, 2.4–8.2). The number of 
active NRTI in the regimen chosen prior to randomization (re-
flecting the extent of resistance to this class) was associated with 
virologic failure; in general, having 1 active NRTI was associated 
with the lowest odds of virologic failure (Supplementary Table 2). 
Participants who started fewer new antiretrovirals had higher odds 
of virologic failure (1–2 new medications vs 4–6, AOR, 6.9 [95% CI, 
2.0–24.0]; 3 vs 4–6, AOR, 3.0 [95% CI, 1.4–6.5]). QOL score was 
not significantly associated with virologic failure in the omit NRTIs 
group; however, in the add NRTIs group, the AOR of virologic 
failure was higher in participants with low baseline QOL scores 
(quartile 1, 0–60 points) versus high QOL scores (quartiles 3 and 
4, 76–100 points): AOR, 5.1 (95% CI, 2.0–13.2); or medium (quar-
tile 2: 61–75 points) versus high scores: AOR, 3.4 (95% CI, 1.2–9.3).
Tropism Changes at Virologic Failure
A total of 177 randomized participants had C-C chemokine 
receptor 5 (CCR5)-tropic  virus at screening; most received a 
regimen containing maraviroc (71% in the add NRTIs group; 
69% in the omit NRTIs group). Within the R5 subgroup, 27 
of 89 participants in the add NRTIs group (30%) and 22 of 88 
participants in the omit NRTIs (25%) experienced virologic 
failure. At virologic failure, only 5 of 45 (11%) who had a tro-
pism result had non-R5 virus.
Treatment-Emergent Resistance Among Participants With Virologic 
Failure
Among the 131 participants across all 3 groups who experi-
enced virologic failure, 9 did not have resistance test results. 
For the 122 participants with results, we assessed changes in 
HIV-1 sensitivity to NRTIs, NNRTIs, and PIs using pheno-
typic testing (Monogram PhenoSense GT) for the randomized 
groups and changes in INSTI resistance using genotyping (for 
participants who received raltegravir) for all groups. For pheno-
typic testing, a drug was considered susceptible if the individual’s 
net assessment from the report was either partially sensitive or 
sensitive. The findings are summarized by antiretroviral class.
NRTI
Treatment-emergent phenotypic resistance to NRTIs at virologic 
failure was uncommon. For example, for tenofovir, in the add 
NRTIs group, 6 participants (11%) with virologic failure had an 
increase in fold-change resistance and 2 (4%) had reversion to less 
resistance; in the omit NRTIs group, 2 participants (4%) had an 
increase in resistance and 5 (10%) had reversion to less resistance.
NNRTI
Eighty-two percent of randomized participants received an an-
tiretroviral regimen containing etravirine. Of the 82 etravirine-
exposed participants who experienced virologic failure and 
had resistance data, 13 (16%) developed treatment-emergent 
etravirine resistance.
PI
Eighty-six percent of participants in the randomized groups 
with virologic failure received ritonavir-boosted darunavir. 
Treatment-emergent darunavir resistance was rare: of the 89 
darunavir-exposed participants with virologic failure, only 3 
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Figure 2. Cumulative probability of virologic failure over time by treatment group. Abbreviation: NRTI, nucleoside reverse transcriptase inhibitor.
INSTI
Among the 131 participants with virologic failure, 116 received 
raltegravir; of these, 104 had integrase genotyping completed 
at baseline and 104 had testing completed at time of virologic 
failure. At baseline, 4 participants (all in the highly resistant 
group) had ≥1 major primary integrase resistance mutation 
(Supplementary Table 3) [4]; 15 participants had ≥1 major ac-
cessory integrase resistance mutation; and 88 participants had 
no mutations. At time of virologic failure, 24 participants had 
≥1 major primary or major accessory mutation; 11 participants 
had both major primary and major accessory mutations (8 of 
these were in the highly resistant group), 4 participants had 1 
major primary mutation (1 in the highly resistant group), and 9 
participants had ≥1 major accessory mutations (none from the 
highly resistant group). The rate of treatment-emergent major 
primary integrase resistance among participants who did not 
have such a mutation at baseline was 11% (11/100).
Effect of NRTIs on Metabolic and Renal Outcomes
We examined the effect of NRTIs on lipids by comparing 
the randomized groups. There was a greater increase in 
total cholesterol from baseline in the omit NRTIs group 
compared to the add NRTIs group (omit NRTIs group 
estimated changes 17 mg/dL higher than add NRTIs group; 
P  =  .0007), non-high-density lipoprotein (HDL) choles-
terol from fasting samples (omit NRTIs estimated changes 
17  mg/dL higher than add NRTIs group P  =  .0013), and 
low-density lipoprotein (LDL) cholesterol (omit NRTIs 
estimated changes 13 mg/dL higher than add NRTIs group, 
P  =  .0026). Ninety-five percent of participants in the add 
NRTIs group received tenofovir disoproxil fumarate (TDF), 
which decreases lipids [5, 6].
We also assessed the Framingham risk score in the 
randomized groups (this was the most widely used cardio-
vascular risk prediction tool at the time of the study). The 
omit NRTIs group had increasingly higher proportions (39% 
at week 24, 43% at week 48, 46% at week 96)  of participants 
with moderate-to-high (>10%) risk scores compared to the add 
NRTIs group (38% at week 24, 40% at week 48, 43% at week 
96) (P = .04 for treatment-by-time interaction), perhaps related
to differences in lipids between the groups.
We examined changes in estimated creatinine clearance 
among participants in the randomized groups. There was 
greater decline in creatinine clearance from baseline in the add 
NRTIs group than in the omit NRTIs group at week 96: mean 
−2.7% vs +1.7% (P = .037).
Quality-of-Life Scores
In all 3 groups, the mean QOL score significantly increased 
from baseline to week 96 (Figure 3). There were no significant 
differences between randomized treatment groups in change in 
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Figure 3. Mean quality of life score and change in quality of life score over time by treatment group. Quality of life was assessed using the general health score, which 
uses a visual analog scale that ranges from 0 (worst possible health) to 100 (perfect health). Abbreviation: NRTI, nucleoside reverse transcriptase inhibitor.
DISCUSSION
The primary results of the OPTIONS trial demonstrated that 
in PWH who have virologic failure on ART and who start a 
regimen with a cumulative activity of >2 active antiretroviral 
medications omitting NRTIs did not result in inferior rates of 
regimen (mostly virologic) failure compared to adding NRTIs 
by 48 weeks. Now, we report the 96-week results of the trial, 
which confirm that HIV-1 salvage therapy can safely omit 
NRTIs without compromising regimen efficacy or durable 
virologic response as long as the new regimen contains a suf-
ficient number of active drugs. The observation that virologic 
failure was uncommon after week 48 (>85% of virologic failures 
occurred before this time point) indicates that, even in highly 
treatment-experienced persons who have drug-resistant HIV-1, 
once virologic suppression is achieved, it is typically sustained.
The number of deaths between treatment initiation and 
96 weeks was lower in the omit NRTIs group than in the add 
NRTIs group but the 95% CIs on the cumulative probability of 
death for this timeframe overlapped. The causes of death were 
heterogeneous and there was no pattern to suggest a common 
mechanism or specific etiology for the imbalance. Additional 
investigations of mitochondrial function and inflammation in 
the 2 groups are underway and will be the topic of a separate 
report.
Several characteristics were associated with virologic failure 
in the randomized groups in OPTIONS. Compared to older 
participants, younger participants were more likely to experi-
ence virologic failure. Previous studies have shown that younger 
people have greater difficulties with adherence [7, 8], suggesting 
enhanced adherence support is needed to improve outcomes 
in this high-risk group. As in previous studies of second-
line therapy (EARNEST, SECOND-LINE, ACTG A5273), in 
OPTIONS having virus with less NRTI resistance at time of 
regimen selection was associated with higher odds of virologic 
failure, perhaps related to poorer adherence [9–11]. Finally, 
starting fewer new antiretroviral medications was associated 
with a higher likelihood of virologic failure, emphasizing the 
importance of using new classes of active medications as part of 
salvage regimens whenever possible.
The importance of active agents in achieving virologic sup-
pression was further demonstrated in the highly resistant group 
who were directly assigned to receive active and partially ac-
tive medications. As expected, this group had lower rates of 
virologic suppression than the randomized groups, where the 
cumulative activity of the regimen was higher. Nevertheless, 
even in the highly resistant group, over half of participants 
achieved HIV-1 RNA <200 copies/mL at week 96, indicating 
that virologic suppression is possible in this difficult-to-treat 
population. Current regimens may yield even more favorable 
results. In OPTIONS, the only integrase inhibitor available 
was raltegravir. Based on results of the SAILING trial [12], 
which showed that dolutegravir was superior to raltegravir in 
participants with previous virologic failure, one would antici-
pate that regimens with dolutegravir would be associated with 
even better virologic outcomes than those seen in OPTIONS.
The OPTIONS trial also confirmed that the frequency of 
treatment-emergent resistance varies by antiretroviral class. In 
participants who received the PI, darunavir, only 3.4% of those 
with virologic failure developed treatment-emergent darunavir 
resistance, a remarkably low proportion and consistent with the 
high barrier to resistance of this class even in highly treatment-
experienced patients. By contrast, 16% of those with virologic 
failure developed treatment-emergent etravirine resistance. 
The rate of treatment-emergent primary major INSTI resist-
ance on raltegravir was similar (11%). These results comport to 
the higher barrier to resistance of boosted PIs as compared to 
NNRTI or first-generation INSTIs, like raltegravir.
We also evaluated QOL scores, which significantly improved 
after starting a new regimen, demonstrating a strong link be-
tween effective treatment and better QOL. Participants in the 
add NRTIs group who had lower QOL at baseline had higher 
likelihood of virologic failure; this association was not observed 
in the omit NRTIs group. One potential explanation is that 
participants with lower QOL were less able to tolerate NRTIs 
leading to higher rates of virologic failure.
Finally, we found expected changes in metabolic and renal 
parameters. Total cholesterol, non-HDL cholesterol, and LDL 
cholesterol levels rose in the omit NRTIs group compared to 
the add NRTIs group, most likely because 95% of those in the 
latter group received TDF, which lowers lipids [5, 6]. There was 
a small decline in creatinine clearance (−2.7%) in the add NRTI 
group, possibly from TDF, which affects renal function [13, 14].
The OPTIONS trial is unique in several aspects: participants 
received 2–3 active agents in the randomized arms and did not 
receive NRTIs in 1 arm. In contrast, recycling of NRTIs was a 
component of most previous treatment-experienced trials: in 
the DUET, RESIST, POWER, MOTIVATE, and BENCHMRK 
trials [15–19], treatment-experienced participants received 
an optimized background regimen with or without a single 
new agent; response rates varied from 34% to 72% at 48 weeks 
and 58% to 62% at 96 weeks. OPTIONS demonstrated sus-
tained virologic responses in the majority of participants even 
without recycling NRTIs—a finding that changed treatment 
guidelines [1].
A limitation of this analysis is that most participants (82%) in 
the add NRTIs group received TDF/emtricitabine; the lipid and 
renal effects we observed would likely not be seen with tenofovir 
alafenamide or abacavir. Strengths of the study include the large 
sample size and the long duration of follow-up.
In conclusion, the 96-week results confirm and extend the 
original findings of the OPTIONS trial: HIV-1 salvage therapy 
can safely omit NRTIs without compromising regimen efficacy 
or durable virologic response as long as the new regimen 
contains a sufficient number of active drugs. We have identified 
specific subgroups at a higher risk of virologic failure; based 
on these findings, more careful attention to younger people 
and those receiving fewer new antiretroviral medications 
is warranted. Ultimately, including newer agents in salvage 
regimens, like second-generation integrase inhibitors or drugs 
against novel targets, are likely to improve virologic outcomes 
even further, leading to sustained virologic suppression in the 
vast majority of treatment-experienced people with HIV-1.
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